Lanvone (Lansoprazole)

Lansoprazole blocks the H+/K+ ATPase enzyme, also known as the gastric proton pump, on the surface of parietal cells in the stomach. This irreversible inhibition stops the final step of acid secretion, leading to a sustained increase in gastric pH and allowing ulcerated or inflamed tissue to recover.

The appropriate dose of Lanvone is determined by the prescribing clinician based on the specific indication, patient age, renal and hepatic function, and other individual factors. Dosage regimens are tailored to each patient and should follow the prescriber's instructions and local prescribing guidelines.

Safety data for lansoprazole in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant. Healthcare providers should evaluate the risk‑benefit profile for each patient and discuss alternatives when appropriate.

To request Lanvone, submit an inquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lanvone (lansoprazole) belongs to the same class as omeprazole, esomeprazole and pantoprazole. All share a similar mechanism of inhibiting the gastric proton pump, but differences exist in pharmacokinetic profiles, drug‑interaction potential and dosing frequency. Choice of agent often depends on clinician preference, patient response and specific drug‑interaction considerations.

Lanvone should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in humid or excessively hot environments.

Lanvone is taken orally, usually as a tablet, with a glass of water. It can be taken with or without food, but consistency with regard to meals is recommended to maintain stable drug absorption. Patients should follow the prescriber’s instructions regarding timing and duration of therapy.

Serious adverse events, although rare, include severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated diarrhoea, and significant liver enzyme elevations. Patients should seek immediate medical attention if they experience symptoms like rash, difficulty breathing, persistent diarrhoea, or jaundice.

Lanvone is contraindicated in patients with known hypersensitivity to lansoprazole or any component of the formulation. Caution is advised for individuals with severe liver disease, those taking medications that have major interactions, and patients with a history of allergic reactions to proton pump inhibitors.